Sunshine Biopharma Inc. Stockholders Equity

• Sunshine Biopharma Inc. showed an increase of +10.8% in Stockholders Equity from 2023 to 2024.
• This data is from Sunshine Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on April 1, 2025.
• XBRL data for this metric is available from 2009 to 2024 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2017: -$616.3 thousand | Q3 2017: -$353.9 thousand | Q1 2018: -$500.7 thousand | Q2 2018: -$276.1 thousand | Q3 2018: $44.7 thousand | Q1 2019: -$211.8 thousand | Q2 2019: -$816.3 thousand | Q3 2019: -$742.9 thousand | Q1 2020: -$708.6 thousand | Q2 2020: -$577.3 thousand | Q3 2020: -$554.9 thousand | Q1 2021: -$1.08 million | Q2 2021: -$872.7 thousand | Q3 2021: -$1.17 million | Q1 2022: $13.31 million | Q2 2022: $41.89 million | Q3 2022: $40.38 million | Q1 2023: $19.43 million | Q2 2023: $23.11 million | Q3 2023: $21.96 million | Q4 2023: $21.21 million | Q1 2024: $24.82 million | Q2 2024: $23.49 million | Q3 2024: $25.04 million | Q4 2024: $23.50 million | Q1 2025: $22.70 million | Q2 2025: $25.68 million | Q3 2025: $24.20 million.
• Historical annual values: Fiscal year 2024: $23.50 million | Fiscal year 2023: $21.21 million | Fiscal year 2022: $21.63 million | Fiscal year 2021: $211.7 thousand | Fiscal year 2020: -$954.8 thousand | Fiscal year 2019: -$735.4 thousand | Fiscal year 2018: -$55.8 thousand | Fiscal year 2017: -$573.4 thousand | Fiscal year 2016: -$209.7 thousand | Fiscal year 2015: -$597.0 thousand | Fiscal year 2014: -$387.6 thousand | Fiscal year 2013: -$7.7 thousand | Fiscal year 2012: $70.4 thousand | Fiscal year 2011: $103.0 thousand | Fiscal year 2010: $196.2 thousand | Fiscal year 2009: $97.8 thousand | Fiscal year 2009: $336.1 thousand | Fiscal year 2009: $0.00.
• Data sourced from SEC EDGAR public filings as of August 8, 2026.

Last verified: August 8, 2026